Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on September 22, 2026 reporting Item 7.01 (Regulation FD Disclosure). Ligand acquired royalty and milestone rights to Santen’s Ryjunea® from Sydnexis.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Ligand acquired royalty and milestone rights to Santen’s Ryjunea® from Sydnexis
- $23 million upfront consideration creates immediate cash outflow for future payment rights
- Transaction expands Ligand’s royalty-based pharmaceutical revenue portfolio
- Exhibit 99.1 contains additional transaction details and expected commercial implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.